Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP4 | P49662 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | CASP9 | P55211 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15712659 | 0.92 | CASP1 (0.49) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL8177410 | 0.89 | DRD2 (0.49) | CASP1CASP3CASP4CASP7CASP9 | |
| Quinoline SCHEMBL28271845 | 0.87 | HTR2C (0.41) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL5782563 | 0.87 | ALOX5 (0.50) | DRD4ALDH1A1 | |
| SCHEMBL15524915 | 0.87 | DRD4 (0.53) | DRD4ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL15524901 | 0.85 | DRD4 (0.48) | DRD4ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL15524921 | 0.84 | DRD4 (0.47) | DRD4ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL15524918 | 0.84 | DRD4 (0.50) | DRD4ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL11358481 | 0.83 | MAPT (0.55) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16494300 | 0.83 | ACHE (0.51) | ALDH1A1LMNAMAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442016-A4 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2005-05-25 | — | — | EP | claimed |
| CN-1568311-A | 1H-Indole Derivatives as Highly Selective Cyclooxygenase-2 Inhibitors | CHEIL JEDANG CORP (KR) | 2005-01-19 | — | — | CN | claimed |
| EP-1442016-A1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | Cheil Jedang Corporation (KR) | 2004-08-04 | — | — | EP | claimed |
| US-20030109568-A1 | 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORPORATION (KR) | 2003-06-12 | — | — | US | claimed |
| WO-2003031409-A1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORPORATION (KR) | 2003-04-17 | — | — | WO | claimed |
| EP-1442016-B1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CHEILJEDANG CORP (KR) | 2010-04-21 | — | — | EP | disclosed |
| CN-100343238-C | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | disclosed |
| CN-1290832-C | 1h-indole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CHEILJEDANG CORP (KR) | 2006-12-20 | — | — | CN | disclosed |
| EP-1442016-A4 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2005-05-25 | — | — | EP | disclosed |
| CN-1585754-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | CN | disclosed |
| CN-1568311-A | 1H-Indole Derivatives as Highly Selective Cyclooxygenase-2 Inhibitors | CHEIL JEDANG CORP (KR) | 2005-01-19 | — | — | CN | disclosed |
| EP-1442016-A1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | Cheil Jedang Corporation (KR) | 2004-08-04 | — | — | EP | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| CN-1335850-A | Quinoline derivatives | SMITHKLINE BEECHMA PLC (GB) | 2002-02-13 | — | — | CN | disclosed |
| EP-1140946-A2 | QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
| EP-1047691-A1 | QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000035919-A2 | QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2000-06-22 | — | — | WO | disclosed |
| CN-1230187-A | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 1999-09-29 | — | — | CN | disclosed |
| WO-1999031086-A1 | QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109568-A1 | 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor | IDO1, IDO2, PTGS1 | CASP1 1643/4885CASP3 3183/4885CASP4 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.